• About Us
  • Contact Us
Today Headline
No Result
View All Result
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
    • Software & IT
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
    • Software & IT
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
No Result
View All Result
TodayHeadline
No Result
View All Result

Lung disease sufferers may be offered first ever treatment thanks to daily pill

1 year ago
in Health News
Reading Time: 5 mins read


Lung disease sufferers with severe breathing problems could be offered first ever treatment for the condition thanks to daily pill

  • Bronchiectasis leads to phlegm building up in the airways, leaving patients bedbound with repeated chest infections; there is no known cure
  • Eventually, it can damage lungs to such an extent that splits form in tissue, causing bleeding; this may lead to respiratory failure – and death
  • Only treatment until now for condition, which affects about 400,000 Britons, has been breathing exercises and repeat courses of antibiotics
  • New daily pill, called brensocatib, could provide real hope

By Cameron Henderson For The Mail On Sunday

Published: 19:02 EDT, 2 July 2022 | Updated: 20:17 EDT, 2 July 2022

Sufferers of a lung disease that causes severe breathing problems and disability are to be offered the first ever treatment for their condition in a trial.

Bronchiectasis leads to phlegm building up in the airways, leaving patients bedbound with repeated chest infections.

There is no known cure, and over time it can damage the lungs to such an extent that splits form in the tissue, causing bleeding. Ultimately, patients can suffer respiratory failure and even death.

Sufferers of a lung disease that causes severe breathing problems and disability are to be offered the first ever treatment for their condition in a trial. Bronchiectasis (CT scan, above) leads to phlegm building up in the airways, leaving patients bedbound with repeated chest infections

Sufferers of a lung disease that causes severe breathing problems and disability are to be offered the first ever treatment for their condition in a trial. Bronchiectasis (CT scan, above) leads to phlegm building up in the airways, leaving patients bedbound with repeated chest infections

Until now, the only treatment for the condition, which affects about 400,000 Britons, has been breathing exercises and repeat courses of antibiotics, but a new daily pill, called brensocatib, may offer real hope.

Professor James Chalmers, who holds a chair in respiratory research at Dundee University and is leading the brensocatib trial, said: ‘Current treatments place a huge burden on patients, with many spending several hours a day performing exercises and inhaling antibiotics.

‘If the new drug is approved, it would be a major landmark in treatment.’

Bronchiectasis is an inflammatory condition that permanently widens the airways and causes the body to produce excess mucus – a sticky substance used to trap pathogens. As a result, bacteria-filled mucus gathers in the lungs, leaving patients prone to chest infections.

To counter this threat, immune cells called neutrophils rush to the lungs.

But rather than engulfing the bacteria as they normally would, the neutrophils react to chemical signals released by the bacteria and explode.

This further congests the lungs, making it harder for the body to clear the infection.

In previous trials, brensocatib was found to halve the number of chest infections patients suffer. Results of the new trial of 1,600 patients are expected next year.

Brensocatib is a new class of drug called a dipeptidyl peptidase 1 (DPP-1) inhibitor. Normally the enzyme DPP-1 signals to the immune system to destroy bacteria, but with bronchiectasis, patients release too many immune compounds and it is this excessive response that eventually damages the lungs.

By blocking the production of DPP-1, the new drug enables the body’s immune system to function normally.

Advertisement

Share or comment on this article:

Related Posts

Health News

Going sober for October? Be careful: Doctor reveals how soft drinks are NOT automatically better for you…

Alcohol free drinks are not...

Read more

New rights for UK donor babies as they turn 18

Why ALL men over 50 should practise pelvic floor exercises to help with issues from a leaky bladder to sex problems

Eating disorders increased during pandemic in female adolescents and adults, says new research

The Best Jackets For Men: Cool Weather Meets Cooler Outerwear

Load More
  • Trending
  • Comments
  • Latest

Jennifer Lopez, 54, flashes cleavage in a plunging Bach Mai floral frock at the Daytime Beauty Awards in Hollywood to honor Tracy Anderson

Liz Truss Accused Of “Corbynite Toryism” And Disrupting Conservative Conference

Class-action suit filed against Binance for alleged harm to FTX before its collapse

The 10 Best Massage Guns of 2023, Rated by Fitness Experts

Pet monkey fed cocaine before getting flushed down toilet

Rachel Maddow speaks on The Rachel Maddow Show.

Rachel Maddow Slays Bothsidesism

Greggs sales jump as cost increases ease back

TSMC’s $72 Billion Rout Has Market Bracing for More

Seahawks’ Witherspoon Drops Brutally Honest One-Liner About Daniel Jones

Why ALL men over 50 should practise pelvic floor exercises to help with issues from a leaky bladder to sex problems

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

Rachel Maddow speaks on The Rachel Maddow Show.

Rachel Maddow Slays Bothsidesism

Greggs sales jump as cost increases ease back

TSMC’s $72 Billion Rout Has Market Bracing for More

Rachel Maddow speaks on The Rachel Maddow Show.

Rachel Maddow Slays Bothsidesism

Greggs sales jump as cost increases ease back

TSMC’s $72 Billion Rout Has Market Bracing for More

  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

No Result
View All Result
  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline